Table 3. Unweighted and Weighted Analyses of Association of Racial Disparities With COVID-19 Severity (Primary Outcome) and 30-Day All-Cause Mortality (Secondary Outcome).
| Analysis | COVID-19 severity, OR (95% CI)a | 30-d mortality | |
|---|---|---|---|
| OR (95% CI)b | RR (95% CI)c | ||
| Unweighted | |||
| Minimally adjustedd | 1.50 (1.29-1.73) | 1.71 (1.39-2.12) | 1.52 (1.29-1.79) |
| Fully adjustede | 1.34 (1.15-1.58) | 1.59 (1.25-2.02) | 1.41 (1.19-1.65) |
| Inverse probability of treatment weightedf | 1.21 (1.11-1.33) | 1.16 (0.94-1.44) | 1.14 (0.95-1.37) |
Abbreviations: OR, odds ratio; RR, relative risk.
ORs comparing COVID-19 severity between non-Hispanic Black vs non-Hispanic White patients were estimated from ordinal logistic regression models; ORs greater than 1 indicate higher COVID-19 severity.
ORs comparing 30-day mortality between non-Hispanic Black vs non-Hispanic White patients were estimated from logistic regression models; ORs greater than 1 indicate higher odds of 30-day all-cause mortality.
RRs comparing 30-day mortality between non-Hispanic Black vs non-Hispanic White patients were estimated from modified Poisson regression models; RRs greater than 1 indicate higher risk of 30-day all-cause mortality.
Adjusted for age (linear and quadratic terms) and sex.
Adjusted for age (linear and quadratic terms), sex, region of patient residence, smoking status, obesity, cardiovascular and pulmonary comorbidities, kidney disease, diabetes, type of malignant neoplasm, Eastern Cooperative Oncology Group performance status, cancer status, timing and modality of anticancer therapy, and month of COVID-19 diagnosis.
Weighted by the reciprocal of the probability of receiving the treatment (ie, race) that was actually received, which was estimated from a propensity score model for race that included age, sex, region of patient residence, smoking status, obesity, cardiovascular and pulmonary comorbidities, kidney disease, diabetes, type of malignant neoplasm, Eastern Cooperative Oncology Group performance status, cancer status, timing and modality of anticancer therapy, and month of COVID-19 diagnosis. Inverse probability of treatment weighted analysis was conducted during manuscript revision.